In the world of microbes, the evolution of resistance to antimicrobial drugs is a process that is nearly inevitable. (1) ...

Our expanding ZORYVE portfolio now encompasses psoriasis, seborrheic dermatitis, and atopic dermatitis, providing physicians ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

A dry scalp can lead to numerous problems, so it’s best to keep it moisturized as much as possible. Here, experts break down six easy ways to keep dryness at bay.

It can be frustrating to deal with annoying flakes on your face. Facial dandruff is a common problem that can make your skin ...

The distinctive appearance of POD usually allows it to be distinguished from other inflammatory facial conditions including rosacea, contact dermatitis, acne, and seborrheic dermatitis (Hafeez ...

Contact dermatitis is characterized by inflammatory skin symptoms that appear after touching an irritating substance or an allergen. It can arise hours to days after contact with the trigger, ...

Scratching beyond the surface: Here’s all you need to know about Atopic Dermatitis as Eczema is on the rise in India. It is not just about itchy skin: Know surprising truth about Atopic ...

(RTTNews) - Arcutis Canada announced that Health Canada has approved ZORYVE for the treatment of seborrheic dermatitis in patients 9 years of age and older. The Health Canada approval is based on ...

Arcutis Biotherapeutics‘ subsidiary, Arcutis Canada, has received Health Canada’s approval for ZORYVE (roflumilast) topical foam 0.3%, to treat seborrheic dermatitis in patients aged nine years and ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a biopharmaceutical company specializing in immuno-dermatology, announced the regulatory approval by Health Canada for ZORYVE (roflumilast) foam 0.3% as a ...